Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
COVID-19: India restricts drug exports amid rising prices of essential bulk drugs; FDA announces first drug shortage
Now that it has been
established that the novel coronavirus is going to globally impact the drug
s
Zhejiang Hisun’s FDA import alert; a new chapter in the fight against data integrity
A few months ago, PharmaCompass covered
the Health Canada request to quarantine drugs linked to lead
